PE20020055A1 - Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal - Google Patents
Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasalInfo
- Publication number
- PE20020055A1 PE20020055A1 PE2001000462A PE2001000462A PE20020055A1 PE 20020055 A1 PE20020055 A1 PE 20020055A1 PE 2001000462 A PE2001000462 A PE 2001000462A PE 2001000462 A PE2001000462 A PE 2001000462A PE 20020055 A1 PE20020055 A1 PE 20020055A1
- Authority
- PE
- Peru
- Prior art keywords
- nasal decongestant
- stable liquid
- solid formulations
- formulations including
- sedating antihistamine
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000133 nasal decongestant Substances 0.000 title abstract 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 title 1
- 230000001387 anti-histamine Effects 0.000 title 1
- 239000000739 antihistaminic agent Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 235000003599 food sweetener Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003765 sweetening agent Substances 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 abstract 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 abstract 1
- 229960005174 ambroxol Drugs 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 230000003419 expectorant effect Effects 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 abstract 1
- 229960003088 loratadine Drugs 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 abstract 1
- 229960003908 pseudoephedrine Drugs 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) DE 0,4mg/ml A 0,7mg/ml DE LORATADINA; b) UN DESCONGESTIONANTE NASAL TAL COMO PSEUDOEFEDRINA, PROPANOLAMINA ; c) UN EXPECTORANTE TAL COMO AMBROXOL Y d) UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION CONTIENE ADEMAS UN AGENTE ANTIMICROBIANO, EDULCORANTE, PROPILENGLICOL Y GLICERINA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA ESTABLE EN FORMA LIQUIDA QUE COMPRENDE UNA COMBINACION DE: a) UN EDULCORANTE TAL COMO SORBITOL, SACARIDO DE SODIO; b) UN VEHICULO LIQUIDO Y c) UN SISTEMA BUFFER PARA MANTENER EL pH EN EL RANGO DE 3 A 5. LA COMPOSICION ES ESTABLE A LA CONTAMINACION DE MICROORGANISMOS DURANTE PERIODOS DE 4 MESES A 36 MESES A TEMPERATURA AMBIENTE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA/A/2000/005129A MXPA00005129A (es) | 2000-05-24 | Composiciones farmaceuticas antihistaminicas - anticongestivas liquidas estables |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020055A1 true PE20020055A1 (es) | 2002-02-12 |
Family
ID=33308448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000462A PE20020055A1 (es) | 2000-05-25 | 2001-05-22 | Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal |
Country Status (7)
| Country | Link |
|---|---|
| AU (1) | AU2001264806A1 (es) |
| BR (1) | BR0111018A (es) |
| CR (1) | CR6804A (es) |
| EC (1) | ECSP024356A (es) |
| PA (1) | PA8517201A1 (es) |
| PE (1) | PE20020055A1 (es) |
| WO (1) | WO2001089527A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635654B1 (en) | 2003-01-09 | 2003-10-21 | Allergan, Inc. | Ophthalmic compositions containing loratadine |
| EP1896022B1 (en) * | 2005-06-17 | 2012-10-31 | AFT Pharmaceuticals Limited | Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion |
| KR20090024282A (ko) * | 2006-06-29 | 2009-03-06 | 쉐링 코포레이션 | 당을 함유하지 않는 저장-안정성 항히스타민성 시럽 |
| EP4281180A4 (en) * | 2021-01-22 | 2024-12-18 | Model Medicines, Inc. | THERAPEUTIC AGENTS AGAINST SARS-COV-2 |
| CN116898799B (zh) * | 2023-08-30 | 2024-04-30 | 哈尔滨圣泰生物制药有限公司 | 一种地氯雷他定口服制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783465A (en) * | 1984-04-09 | 1988-11-08 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| BR9407414A (pt) * | 1993-09-07 | 1996-11-12 | Procter & Gamble | Composições contendo um sal de aminoácido de agente antiinflamatório não-esteroide de ácido propiônico e pelo menos um descongestionante um expectorante um anti-histamina e um antitussivo |
| JP2000505104A (ja) * | 1996-10-31 | 2000-04-25 | シェーリング コーポレイション | 喘息の治療のためのロラタジンおよび充血除去剤を含む組成物 |
| US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| US6051585A (en) * | 1998-12-07 | 2000-04-18 | Weinstein; Robert E. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| AU2000242484B2 (en) * | 2000-04-14 | 2006-02-09 | J-Med Pharmaceuticals, Inc. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
-
2001
- 2001-05-22 PE PE2001000462A patent/PE20020055A1/es not_active Application Discontinuation
- 2001-05-22 PA PA20018517201A patent/PA8517201A1/es unknown
- 2001-05-22 AU AU2001264806A patent/AU2001264806A1/en not_active Withdrawn
- 2001-05-22 BR BR0111018-7A patent/BR0111018A/pt not_active Application Discontinuation
- 2001-05-22 WO PCT/US2001/016570 patent/WO2001089527A2/en active Application Filing
-
2002
- 2002-10-31 CR CR6804A patent/CR6804A/es not_active Application Discontinuation
- 2002-11-22 EC EC2002004356A patent/ECSP024356A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001264806A1 (en) | 2001-12-03 |
| WO2001089527A2 (en) | 2001-11-29 |
| PA8517201A1 (es) | 2002-08-26 |
| WO2001089527A3 (en) | 2003-10-16 |
| ECSP024356A (es) | 2003-03-31 |
| CR6804A (es) | 2008-10-29 |
| BR0111018A (pt) | 2004-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4600739A1 (es) | Formulaciones liquidas orales a base de alendronato | |
| ES2194732T3 (es) | Composiciones farmaceuticas orales de liberacion controlada de mesalazina. | |
| PE20010053A1 (es) | Formulacion de amoxicilina y clavulanato de potasio | |
| CR6656A (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
| ES2193726T3 (es) | Formulaciones de aerosol medicinales. | |
| ES2176684T3 (es) | Nuevas asociaciones de principios activos que contienen clopidogrel y un antitrombotico. | |
| ES2181473T3 (es) | Formulaciones liquidas estables de la toxina botulinica. | |
| NO20011471D0 (no) | Nye orale vedvarende frigivelsesformuleringer | |
| BR9611523A (pt) | Meios de administração para drogas analgésicas, antiinflamatórias e antipiréticas contendo óxido nitroso e composições farmacêuticas contendo tais meios e drogas. | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| ES2197792B1 (es) | Formulaciones farmaceuticas que contienen morfina intranasal. | |
| BR9912694A (pt) | Composto para preparar medicamento de administração pulmonar | |
| AR035034A1 (es) | Composicion farmaceutica liquida | |
| PE88699A1 (es) | Formas de dosificacion de liberacion sostenida de sertralina | |
| ITMI20021392A1 (it) | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' | |
| ES2110212T3 (es) | Composicion farmaceutica efervescente que contiene ibuprofeno y su procedimiento de preparacion. | |
| BR9913135A (pt) | Formulação oral | |
| PE20020055A1 (es) | Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal | |
| PE20030545A1 (es) | Formulaciones de jarabe de ribavirina | |
| ES2142430T3 (es) | Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral. | |
| RS50246B (sr) | Tableta za sisanje, koja sadrži ambroksol | |
| CO5550418A2 (es) | Formulaciones antihistaminicas para formas de dosificacion de capsula blanda | |
| AR087240A2 (es) | Composiciones farmaceuticas que tienen epinastina y pseudoefedrina | |
| ES2099649T3 (es) | Nueva composicion farmaceutica destinada para la fabricacion de un polvo estable que contiene, a titulo de ingrediente activo, una asociacion de acido acetilsalicilico y de metoclopramida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |